GEP20063860B - Chemically-modified human growth hormone conjugates - Google Patents
Chemically-modified human growth hormone conjugatesInfo
- Publication number
- GEP20063860B GEP20063860B GE5599A GEAP2002005599A GEP20063860B GE P20063860 B GEP20063860 B GE P20063860B GE 5599 A GE5599 A GE 5599A GE AP2002005599 A GEAP2002005599 A GE AP2002005599A GE P20063860 B GEP20063860 B GE P20063860B
- Authority
- GE
- Georgia
- Prior art keywords
- growth hormone
- human growth
- chemically
- modified human
- conjugate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33190701P | 2001-11-20 | 2001-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEP20063860B true GEP20063860B (en) | 2006-06-26 |
Family
ID=23295870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GE5599A GEP20063860B (en) | 2001-11-20 | 2002-11-20 | Chemically-modified human growth hormone conjugates |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1453859A2 (https=) |
| JP (2) | JP2005525302A (https=) |
| KR (2) | KR20050044858A (https=) |
| CN (1) | CN1608079A (https=) |
| AP (1) | AP2004003050A0 (https=) |
| AU (1) | AU2002356990A1 (https=) |
| BR (1) | BR0214451A (https=) |
| CA (1) | CA2467731A1 (https=) |
| CO (1) | CO5580794A2 (https=) |
| EA (2) | EA200700431A1 (https=) |
| EC (1) | ECSP045114A (https=) |
| GE (1) | GEP20063860B (https=) |
| HR (1) | HRP20040448A2 (https=) |
| HU (1) | HUP0500997A2 (https=) |
| IL (1) | IL162031A0 (https=) |
| IS (1) | IS7268A (https=) |
| MA (1) | MA27544A1 (https=) |
| MX (1) | MXPA04004809A (https=) |
| NO (1) | NO20042182L (https=) |
| OA (1) | OA13063A (https=) |
| PL (1) | PL374354A1 (https=) |
| RS (1) | RS53104A (https=) |
| TN (1) | TNSN04090A1 (https=) |
| WO (1) | WO2003044056A2 (https=) |
| ZA (1) | ZA200403907B (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030171285A1 (en) * | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
| US7041855B2 (en) | 2001-12-11 | 2006-05-09 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
| AU2002357806A1 (en) * | 2001-12-11 | 2003-06-23 | Sun Bio, Inc. | Novel monofunctional polyethylene glycol aldehydes |
| US6956135B2 (en) | 2001-12-11 | 2005-10-18 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
| US6916962B2 (en) | 2001-12-11 | 2005-07-12 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
| EE05509B1 (et) * | 2002-01-18 | 2012-02-15 | Biogen@Idec@Ma@Inc | Aktiveeritud polalkleenglkoolpolmeer ja seda sisaldavad kompositsioonid |
| NZ540490A (en) | 2002-09-09 | 2007-10-26 | Nektar Therapeutics Al Corp | Water-soluble polymer alkanal conjugates with human growth hormone |
| EP1591467A1 (en) * | 2002-09-09 | 2005-11-02 | Nektar Therapeutics Al, Corporation | Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone |
| US20040142870A1 (en) * | 2002-11-20 | 2004-07-22 | Finn Rory F. | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
| US20050281778A1 (en) * | 2003-03-28 | 2005-12-22 | Myung-Ok Park | Human growth hormone conjugated with biocompatible polymer |
| US7524813B2 (en) | 2003-10-10 | 2009-04-28 | Novo Nordisk Health Care Ag | Selectively conjugated peptides and methods of making the same |
| CN100580087C (zh) * | 2003-10-10 | 2010-01-13 | 诺和诺德医疗保健公司 | 肽的缀合 |
| EP2033662B1 (en) * | 2004-01-21 | 2012-10-17 | Novo Nordisk Health Care AG | Transglutaminase mediated conjugation of peptides |
| JP2008511610A (ja) * | 2004-08-31 | 2008-04-17 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | グリセロール分岐のポリエチレングリコール−ヒト成長ホルモン結合体、それらの製造方法及び使用方法 |
| GB2438760A (en) * | 2004-12-22 | 2007-12-05 | Ambrx Inc | Methods for expression and purification of recombinant human growth hormone |
| JP2008525473A (ja) | 2004-12-22 | 2008-07-17 | アンブレツクス・インコーポレイテツド | 修飾されたヒト成長ホルモン |
| EP1828224B1 (en) | 2004-12-22 | 2016-04-06 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| EP1850878A2 (en) | 2005-02-10 | 2007-11-07 | Novo Nordisk A/S | C-terminally pegylated growth hormones |
| AU2006237329B2 (en) | 2005-04-18 | 2012-04-12 | Novo Nordisk A/S | IL-21 variants |
| CN101268098A (zh) * | 2005-08-30 | 2008-09-17 | 诺沃-诺迪斯克保健股份有限公司 | 聚乙二醇化生长激素的液体制剂 |
| CN104710503B (zh) * | 2005-11-08 | 2023-04-25 | Ambrx 公司 | 用于修饰非天然氨基酸和非天然氨基酸多肽的促进剂 |
| DK1968635T3 (en) | 2005-12-14 | 2014-12-15 | Ambrx Inc | Compositions and Methods of, and uses of non-natural amino acids and polypeptides |
| BRPI0713963A2 (pt) * | 2006-07-07 | 2012-11-27 | Novo Nordisk Healthcare Ag | conjugados de proteìna e métodos para sua preparação |
| CN101108895B (zh) * | 2006-07-19 | 2011-10-26 | 北京键凯科技有限公司 | 聚乙二醇乙醛衍生物及其与药物的结合物 |
| AU2007310777A1 (en) | 2006-10-26 | 2008-05-02 | Novo Nordisk A/S | IL-21 variants |
| CL2008002399A1 (es) | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c. |
| US9840546B2 (en) | 2008-04-03 | 2017-12-12 | Biosteed Gene Expression Tech. Co., Ltd. | Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof |
| HRP20161040T1 (hr) | 2008-04-29 | 2016-12-16 | Ascendis Pharma Growth Disorders Division A/S | Pegilirani rekombinantni spojevi ljudskog hormona rasta |
| KR101104574B1 (ko) * | 2008-05-14 | 2012-01-11 | 성균관대학교산학협력단 | 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도 |
| MY156568A (en) * | 2008-07-31 | 2016-03-15 | Pharmaessentia Corp | Peptide-polymer conjugates |
| KR20110039348A (ko) | 2008-08-06 | 2011-04-15 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질 |
| RU2409669C9 (ru) * | 2008-08-18 | 2012-05-27 | ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") | Способ иммобилизации биологически активного вещества (бав) на носитель (варианты) и конъюгат бав-носитель, полученный данными способами |
| US8492503B2 (en) * | 2008-09-11 | 2013-07-23 | Nektar Therapeutics | Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method |
| JP5816097B2 (ja) | 2009-01-22 | 2015-11-18 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 安定な成長ホルモン化合物 |
| JP6086528B2 (ja) | 2009-08-06 | 2017-03-01 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 長期のインビボ有効性を有する成長ホルモン |
| CA2783296C (en) | 2009-12-15 | 2019-01-15 | Ascendis Pharma As | Growth hormone composition |
| JP5980689B2 (ja) | 2010-01-22 | 2016-08-31 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 安定な成長ホルモン化合物 |
| CN118767117A (zh) | 2010-01-22 | 2024-10-15 | 诺沃—诺迪斯克保健股份有限公司 | 体内功效延长的生长激素 |
| CA2798518A1 (en) * | 2010-05-17 | 2011-11-24 | Cebix, Inc. | Pegylated c-peptide |
| EP2446898A1 (en) | 2010-09-30 | 2012-05-02 | Laboratorios Del. Dr. Esteve, S.A. | Use of growth hormone to enhance the immune response in immunosuppressed patients |
| EA019967B1 (ru) * | 2011-12-21 | 2014-07-30 | Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") | Ковалентный конъюгат полиэтиленгликоля с гормоном роста человека |
| US11045523B2 (en) | 2013-04-05 | 2021-06-29 | Novo Nordisk Healthcare Ag | Formulation of growth hormone albumin-binder conjugate |
| US11559567B2 (en) | 2014-11-06 | 2023-01-24 | Pharmaessentia Corporation | Dosage regimen for pegylated interferon |
| IL251906B2 (en) | 2014-11-18 | 2024-04-01 | Ascendis Pharma Endocrinology Div A/S | Novel polymeric hgh prodrugs |
| DK3220892T3 (da) | 2014-11-21 | 2021-11-08 | Ascendis Pharma Endocrinology Div A/S | Langtidsvirkende væksthormondoseringsformer |
| MA41957A (fr) * | 2015-03-11 | 2018-02-28 | Nektar Therapeutics | Conjugués d'une fraction d'il-7 et d'un polymère |
| SG11201802180TA (en) * | 2015-09-18 | 2018-04-27 | Univ Miyazaki | Long-acting adrenomedullin derivative |
| CA3131817A1 (en) | 2019-03-04 | 2020-09-10 | Ascendis Pharma Endocrinology Division A/S | Long-acting growth hormone dosage forms with superior efficacy to daily somatropin |
| CN114539384B (zh) * | 2020-11-19 | 2024-09-06 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇化长效生长激素及其制备方法和医药应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| EP0458064B1 (en) * | 1990-05-04 | 1998-02-25 | American Cyanamid Company | Stabilization of somatotropins by modification of cysteine residues |
| WO1992016555A1 (en) * | 1991-03-18 | 1992-10-01 | Enzon, Inc. | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
| WO1993000109A1 (en) * | 1991-06-28 | 1993-01-07 | Genentech, Inc. | Method of stimulating immune response using growth hormone |
| NZ250375A (en) * | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
| US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| CA2230492C (en) * | 1995-09-21 | 2009-05-26 | Genentech, Inc. | Human growth hormone variants |
| ATE375363T1 (de) * | 1997-07-14 | 2007-10-15 | Bolder Biotechnology Inc | Derivate des wachstumshormons und verwandte proteine |
| BR122013003013B8 (pt) * | 1999-01-14 | 2021-07-06 | Bolder Biotechnology Inc | proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção |
| JP2002540065A (ja) * | 1999-01-29 | 2002-11-26 | アムジェン インコーポレーテッド | Ｇｃｓｆコンジュゲート |
| WO2001076639A2 (en) * | 2000-04-06 | 2001-10-18 | Pharmacia Corporation | Chemically-modified myelopoietin conjugates |
| EP1352062A2 (en) * | 2001-01-11 | 2003-10-15 | Maxygen Aps | Improved growth hormone molecules |
-
2002
- 2002-11-20 AP APAP/P/2004/003050A patent/AP2004003050A0/en unknown
- 2002-11-20 OA OA1200400143A patent/OA13063A/en unknown
- 2002-11-20 WO PCT/US2002/037270 patent/WO2003044056A2/en not_active Ceased
- 2002-11-20 KR KR1020047007708A patent/KR20050044858A/ko not_active Abandoned
- 2002-11-20 RS YU53104A patent/RS53104A/sr unknown
- 2002-11-20 IL IL16203102A patent/IL162031A0/xx unknown
- 2002-11-20 EP EP02803695A patent/EP1453859A2/en not_active Withdrawn
- 2002-11-20 MX MXPA04004809A patent/MXPA04004809A/es not_active Application Discontinuation
- 2002-11-20 GE GE5599A patent/GEP20063860B/en unknown
- 2002-11-20 HR HR20040448A patent/HRP20040448A2/hr not_active Application Discontinuation
- 2002-11-20 HU HU0500997A patent/HUP0500997A2/hu unknown
- 2002-11-20 JP JP2003545691A patent/JP2005525302A/ja active Pending
- 2002-11-20 EA EA200700431A patent/EA200700431A1/ru unknown
- 2002-11-20 BR BRPI0214451-4A patent/BR0214451A/pt not_active IP Right Cessation
- 2002-11-20 EA EA200400565A patent/EA008505B1/ru unknown
- 2002-11-20 AU AU2002356990A patent/AU2002356990A1/en not_active Abandoned
- 2002-11-20 CN CNA028259289A patent/CN1608079A/zh active Pending
- 2002-11-20 KR KR1020077011730A patent/KR20070072924A/ko not_active Withdrawn
- 2002-11-20 CA CA002467731A patent/CA2467731A1/en not_active Abandoned
- 2002-11-20 PL PL02374354A patent/PL374354A1/xx unknown
-
2004
- 2004-05-17 IS IS7268A patent/IS7268A/is unknown
- 2004-05-19 MA MA27686A patent/MA27544A1/fr unknown
- 2004-05-20 ZA ZA200403907A patent/ZA200403907B/en unknown
- 2004-05-20 CO CO04046633A patent/CO5580794A2/es not_active Application Discontinuation
- 2004-05-20 TN TNP2004000090A patent/TNSN04090A1/fr unknown
- 2004-05-20 EC EC2004005114A patent/ECSP045114A/es unknown
- 2004-05-26 NO NO20042182A patent/NO20042182L/no not_active Application Discontinuation
-
2006
- 2006-07-14 JP JP2006193577A patent/JP2006321808A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0500997A2 (en) | 2007-11-28 |
| AU2002356990A1 (en) | 2003-06-10 |
| ZA200403907B (en) | 2007-12-27 |
| RS53104A (sr) | 2006-10-27 |
| JP2005525302A (ja) | 2005-08-25 |
| JP2006321808A (ja) | 2006-11-30 |
| ECSP045114A (es) | 2004-07-23 |
| TNSN04090A1 (fr) | 2006-06-01 |
| PL374354A1 (en) | 2005-10-17 |
| BR0214451A (pt) | 2006-05-30 |
| KR20070072924A (ko) | 2007-07-06 |
| IS7268A (is) | 2004-05-17 |
| HRP20040448A2 (en) | 2006-02-28 |
| WO2003044056A2 (en) | 2003-05-30 |
| MA27544A1 (fr) | 2005-10-03 |
| CN1608079A (zh) | 2005-04-20 |
| OA13063A (en) | 2006-11-10 |
| CA2467731A1 (en) | 2003-05-30 |
| WO2003044056A3 (en) | 2003-08-21 |
| NO20042182L (no) | 2004-08-11 |
| EA200400565A1 (ru) | 2005-06-30 |
| AP2004003050A0 (en) | 2004-06-30 |
| CO5580794A2 (es) | 2005-11-30 |
| EP1453859A2 (en) | 2004-09-08 |
| EA008505B1 (ru) | 2007-06-29 |
| EA200700431A1 (ru) | 2008-02-28 |
| KR20050044858A (ko) | 2005-05-13 |
| IL162031A0 (en) | 2005-11-20 |
| MXPA04004809A (es) | 2004-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20063860B (en) | Chemically-modified human growth hormone conjugates | |
| CA2078347C (en) | Use of copper(ii) containing compounds to accelerate wound healing | |
| BG104484A (bg) | Сайт - специфично получаване на конюгати от полиетилен- гликол - grf | |
| JPH02504279A (ja) | インスリン様成長因子１（ｉｇｆ‐１）または因子２（ｉｇｆ‐２）の類縁ペプチド | |
| CY1106723T1 (el) | Ν-τελικα μονοπεγυλιωμενα συζευγματα ανθρωπινης αυξητικης ορμονης, διεργασιες για την παρασκευη τους και μεθοδοι χρησης αυτων | |
| ATE245697T1 (de) | Klonierung und expression eines gens, das bryodin 1 aus bryonia dioica kodiert | |
| CA2345027A1 (en) | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility | |
| MXPA02006215A (es) | Metodo para preparar esteres de 1-benzotriazolil carbonato de poli(etilenglicol). | |
| AR044024A1 (es) | Mutante de sustitucion de la il-18 humana, composicion biologicamente activa que la comprende, su uso para preparar dicha composicion, metodo para prepararla y metodo para mejorar la farmacocinetica y farmacodinamica de dicha il-18 humana | |
| NZ517012A (en) | Peptides that lower blood glucose levels | |
| KR20070108535A (ko) | 폴리펩티드와 5당류의 접합체 | |
| WO2003061577A3 (en) | Polyalkylene glycol with moiety for conjugating biologically active compound | |
| GB2355009A (en) | Peptides conjugated to bile acids/salts | |
| AU5956398A (en) | Remedies for lymphocytic tumors | |
| AU2005232475A1 (en) | Novel g-csf conjugates | |
| EP1382352A1 (de) | Bisacyloxypropylcystein-Konjugate und deren Verwendung | |
| US7829074B2 (en) | Hydroxypatite-targeting poly(ethylene glycol) and related polymers | |
| AR042103A1 (es) | Conjugados de hormona de crecimiento humana pegilados n- terminales y proceso para su preparacion | |
| YU68702A (sh) | Novi lhrh-antagonisti, njihova proizvodnja i upotreba kao leka | |
| KR890700606A (ko) | 생물학적 활성분자 | |
| BR0213821A (pt) | Conjugados de polìmero/peptìdeo timosina alfa 1 | |
| KR960000921A (ko) | 칼시토닌 유도체 및 그 용도 | |
| EP1763535B1 (de) | Mit einem organischem rest verbundenes polypeptid | |
| CA2498062A1 (en) | Conjugates of insulin-like growth factor binding protein-4 and poly(ethylene glycol) | |
| PT918795E (pt) | Droga antiangiogenica para tratar cancro artrite e retinopatia |